1. Home
  2. BBNX vs TCPC Comparison

BBNX vs TCPC Comparison

Compare BBNX & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBNX
  • TCPC
  • Stock Information
  • Founded
  • BBNX 2015
  • TCPC 2006
  • Country
  • BBNX United States
  • TCPC United States
  • Employees
  • BBNX N/A
  • TCPC N/A
  • Industry
  • BBNX Medical/Dental Instruments
  • TCPC Finance/Investors Services
  • Sector
  • BBNX Health Care
  • TCPC Finance
  • Exchange
  • BBNX Nasdaq
  • TCPC Nasdaq
  • Market Cap
  • BBNX 578.8M
  • TCPC 665.8M
  • IPO Year
  • BBNX 2025
  • TCPC 2012
  • Fundamental
  • Price
  • BBNX $16.40
  • TCPC $7.13
  • Analyst Decision
  • BBNX Strong Buy
  • TCPC Hold
  • Analyst Count
  • BBNX 10
  • TCPC 4
  • Target Price
  • BBNX $24.40
  • TCPC $7.50
  • AVG Volume (30 Days)
  • BBNX 553.4K
  • TCPC 434.9K
  • Earning Date
  • BBNX 07-29-2025
  • TCPC 08-07-2025
  • Dividend Yield
  • BBNX N/A
  • TCPC 16.55%
  • EPS Growth
  • BBNX N/A
  • TCPC N/A
  • EPS
  • BBNX N/A
  • TCPC N/A
  • Revenue
  • BBNX $69,830,000.00
  • TCPC $259,596,996.00
  • Revenue This Year
  • BBNX $32.71
  • TCPC N/A
  • Revenue Next Year
  • BBNX $37.37
  • TCPC N/A
  • P/E Ratio
  • BBNX N/A
  • TCPC N/A
  • Revenue Growth
  • BBNX 38911.17
  • TCPC 20.88
  • 52 Week Low
  • BBNX $8.89
  • TCPC $6.27
  • 52 Week High
  • BBNX $24.50
  • TCPC $10.60
  • Technical
  • Relative Strength Index (RSI)
  • BBNX N/A
  • TCPC 29.45
  • Support Level
  • BBNX N/A
  • TCPC $7.55
  • Resistance Level
  • BBNX N/A
  • TCPC $7.41
  • Average True Range (ATR)
  • BBNX 0.00
  • TCPC 0.16
  • MACD
  • BBNX 0.00
  • TCPC -0.07
  • Stochastic Oscillator
  • BBNX 0.00
  • TCPC 14.77

About BBNX Beta Bionics Inc. Common Stock

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.

Share on Social Networks: